Latest news with #Hemostemix
Yahoo
31-07-2025
- Health
- Yahoo
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term performance of brain-computer interfaces (BCIs). Key Scientific Insights The Challenge with BCIs: Inflammation, scarring, and programmed cell death undermine performance over timeImplantable electrodes within the brain have enabled remarkable achievements—e.g., paralyzed individuals playing chess and blind individuals recognizing letters. However, these devices often fail between six months and one year. The longest BCI in use lasted seven years. Even then, issues like inflammation, scarring, and programmed cell death (apoptosis) undermine performance over time. Hemostemix's Innovative Cell-Based SolutionThe article proposes using two types of autologous (patient-derived) progenitor cells: Angiogenic Cell Precursors (ACP-01, VesCell™) and Neural Cell Precursors (NCP-01), delivered into the cerebrospinal fluid, to foster a healing cellular environment around the implant. ACP-01 (VesCell™) produces signals like IL-8, VEGF, and angiogenin. They attract natural killer (NK) cells that suppress inflammation, reduce tissue scarring, and support new blood vessel growth (angiogenesis). ACP-01potentiate healing through the expression of tissue regeneration factors CXCL8, VEGF, and angiogenin. They include CD34+ (blood stem cell). CXCL8 recruit endogenous CD34+, that circulate peripherally, to the site of implant. CXCL8 (interleukin-8) activate NF-κB, resulting in gene transcription and protein synthesis necessary for learning (memory formation and consolidation). NCP- 01express receptors like CXCR4, and migrate toward the BCI site. NCP help shift immune cells into a neuroprotective (M2) state. NCP differentiate into neurons and supporting glial cells that promote new synaptic connections and neural plasticity. Figure 1. Natural Killer (NK) cells recruited by angiogenic cell precursors (ACPs) suppress inflammation through the release of anti-inflammatory cytokines, dendritic cell and monocyte maturation, and lysis of auto-aggressive T cells. Created in BioRender. Tuchman, K. (2025) view an enhanced version of this graphic, please visit: Figure 2. Angiogenic cell precursors (ACPs) potentiate healing through expression of tissue regeneration factors such as the chemokine interleukin-8 (CXCL8), vascular endothelial growth factor (VEGF) and angiogenin. In addition to the robust presence of CD34+ in ACPs, the expressed CXCL8 recruits peripheral CD34+ precursor cells, further supporting angiogenesis. Created by BioRender. Tuchman, K. (2025) view an enhanced version of this graphic, please visit: Figure 3. Interleukin-8 (CXCL8) is expressed by angiogenic cell precursors (ACPs), and activatesthe canonical NF-κB pathway, resulting in gene transcription and protein synthesis necessary formemory formation and consolidation. Created in BioRender. Tuchman, K. (2025) view an enhanced version of this graphic, please visit: Mechanism of Action Together, ACP and NCP support a cascade of beneficial molecular events: Activation of neurotrophic factors and NF-κB pathways that protect cells (anti-apoptosis). Promotion of synaptogenesis (formation of connections between neurons), neuritogenesis (growth of neural processes), to improve learning-related plasticity. As the patient's DNA-based engineered cellular environment, ACP and NCP home to the site of BCI, decrease inflammation, increase angiogenesis, increase neuro-protectiveness, promote new synaptic connections, and may dramatically extend both the lifespan of BCI, signal fidelity and learning. Why This Matters to Hemostemix Hemostemix's patented proprietary platform produces ACP-01 (angiogenic precursors) and NCP-01 (neural precursors) from a patient's own blood. This new research provides a scientific basis of how the combination of ACP-01+NCP-01 promises to overcome the major limitations in BCI implants. The findings align with Hemostemix's vision of licensing ACP-01 and NCP-01 to enhance BCI longevity and functionalities. Forward-Looking Perspective This research paves the way for: Licensing with BCI technology companies to combine autologous stem-cell support of BCI with cutting-edge patient-based angiogenic and neural interfaces. Rapid preclinical and clinical testing of ACP-01 + NCP-01 at BCI implant sites. "We imagine a world where the environment for BCI, the patient's brain, augmented by the patients' own stem cells, improves the longevity of the implants from months to a lifetime, improves signal fidelity to increase functional movement, and increases learning and memory retention," stated Dr. Fraser Henderson, lead author. "I want to thank Dr. Henderson and Ms. Tuchman for this very thorough exposition of the benefits of using one's own DNA structured as ACP & NCP to improve BCIs. Truly, this is incredible work. Coupled with our market analyses of the top three BCI companies, shareholders can expect more news to follow, as Mr. Lawrence, Chief Commercialization Officer and I meet with potential partners," stated Thomas Smeenk, CEO. In Summary Dr. Henderson has outlined a new cell-based approach that may allow brain implants to work reliably for years. By delivering two types of the patient's blood-derived stem cell precursors—one that fights inflammation and boosts blood flow, the other that helps build new neuronal cells—this method could protect and improve the brain at the site of BCI implant. Hemostemix's ready-to-use cell products (ACP-01 and NCP-01) are a direct fit for this approach and could potentially transform how long and well brain-computer interfaces function. ABOUT HEMOSTEMIX Founded in 2003, Hemostemix is a stem-cell therapeutics company with patented technology to generate autologous angiogenic and neural cell precursors from patient blood. Its ACP-01 and NCP-01 cell lines aim to treat cardiovascular, neurological, and implant-related conditions. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the publication in CELLS of the properties of ACP-01+NCP-01 and the improvement of brain computer interface (BCI) technologies. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit
Yahoo
04-07-2025
- Business
- Yahoo
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-07-2025
- Health
- Yahoo
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
Florida SB 1768 Becomes Law: Hemostemix Inc. Begins Commercial Offering of ACP-01 (VesCell) for Ischemic Pain Treatments in Florida. Calgary, Alberta--(Newsfile Corp. - July 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company focused on autologous stem cell therapies for cardiovascular diseases, is pleased to announce that Florida Senate Bill 1768 has officially become law on July 1, which enables the commercial sales of VesCell (ACP-01) in the state of Florida. The Company is on track to offer first commercial treatments by Q4 2025 and now projects sales of $22,500,000 in 2026 with the ability to outperform the forecast by continuing to sell forward its therapy convertible debentures (TCDs), offer payment plans, and offer financial assistance to economically disadvantaged individuals. Florida SB 1768 affirms the right of patients and their physicians to access autologous stem cell therapies that are not yet FDA-approved, provided patients give informed consent and physicians disclose the investigational nature of the treatment. Under the new law, licensed Florida physicians may administer ACP-01 (VesCell) to treat pain associated with conditions of ischemia, including: Peripheral Arterial Disease (PAD) Chronic Limb Threatening Ischemia (CLTI) Angina Congestive Heart Failure Ischemic and Non-Ischemic Dilated Cardiomyopathy Peripheral Neuropathy related to Total Body Ischemia "This landmark legislation makes Florida the most progressive state in the U.S.A. for regenerative medicine," said Thomas Smeenk, CEO of Hemostemix Inc. "We are proud to provide VesCell (ACP-01), as a proven therapy that restores microcirculation, reduces ischemic pain, and improves patient function. We will continue to sell TCDs forward. Very soon we will offer payment plans, and financial assistance to economically disadvantaged individuals. We will put significant emphasis on following each patient to collect the data to fast track FDA approval, as we comply with all aspects of the law and regulatory environment," Smeenk said. Legal Compliance Requirements To comply with Florida SB 1768: Physicians must provide patients with a state-mandated disclosure notice that VesCell is not FDA-approved. Patients must sign an informed consent form acknowledging the investigational nature of the therapy. The treatment must be performed in licensed medical facilities under the supervision of a physician. ACP-01 is produced at a GMP-certified and FDA-audited facility, a legal requirement, using a patented process to isolate, expand, and formulate angiogenic cell precursors from the patient's blood. The therapy is returned to the treating physician in sterile ready-to-use syringes, in temperature-controlled packaging with full QA/QC documentation and traceability. "With 498 patients treated to-date and published results demonstrating safety, improvement in cardiac function, mobility, and pain reduction, ACP-01 is positioned to be the #1 therapy for patients with no other treatment options," Croom Lawrence stated. Pain Reduction in Chronic Limb Threatening Ischemia (Phase II). Ulcer Size Reduction: Patients treated with ACP-01 saw ulcer sizes decrease from an average of 1.46 cm² to 0.48 mm² within three months, with a statistically significant p-value of 0.01. The placebo group showed no significant change. Amputation and Mortality Rates: At one year, the ACP-01 group had a 4.8% amputation rate (1/21 patients) and a 4.8% mortality rate (1/21), compared to 25% amputation (2/8) and 12.5% mortality (1/8) in the placebo group. Safety Profile: No treatment-related complications were reported, reinforcing the therapy's safety alongside its efficacy. Hemostemix is championing Florida's progressive stance to anchor U.S. clinical strategy. Learn more, join our community, or enrol today at Medical Contact: Croom Lawrence, CCO, clawrence@ (540) 878-6754 ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, ACP-01. Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder EM: tsmeenk@ PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-06-2025
- Business
- Yahoo
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen is an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. Clinically, ACP-01 has been observed to reverse vascular dementia for more than ten years in one patient (Mrs L.). About Croom Lawrence Croom Lawrence is a seasoned biopharmaceutical executive with over 25 years of experience driving commercialization strategies across regenerative medicine, cell therapy, advanced biologics and diagnostics. He has successfully launched multiple breakthrough therapies, built and led high-performing global marketing and sales teams, and secured strategic partnerships with top-tier pharma and healthcare providers. His deep understanding of market access, reimbursement, and regulatory navigation positions him as a key asset to Hemostemix. By leveraging Croom's expertise, Hemostemix can accelerate the global adoption of ACP-01, expand its clinical and commercial footprint, and build sustainable revenue channels that align with our mission to restore health and save lives. "I am very pleased to welcome Croom Lawrence as our Chief Commercialization Officer. Croom brings a rare blend of strategic insight and executional excellence, honed through decades of leadership in biotech commercialization. His track record in building global markets, negotiating complex partnerships, and accelerating the path from bench to bedside is unmatched. With Croom leading our commercialization efforts, Hemostemix is poised to unlock the full value of ACP-01 and transform patient care worldwide. The revenue share agreement with MCI Screen generates immediate significant revenue synergies," Smeenk said. Revenue Sharing Hemostemix and (Croom Lawrence) have agreed to share revenue from each cognitive assessment such that 57% of revenue is allocated to and 43% of revenue is allocated to Hemostemix from each patient examination, globally, assessed for an ACP-01 treatment. adds to Hemostemix's Ability to Screen for Vascular Dementia Powered by a normative database of 2 million data points, advanced cognitive test is 97.3% accurate in detecting memory and cognitive impairments. Physicians who assess patients according to Hemostemix's inclusion and exclusion criteria will use the Memory Performance Index (MPI) scores and other diagnostics to determine if they meet the Phase I Vascular Dementia inclusion criteria. A New Path Forward for Patients and Families "This is a highly accurate assessment that is completed in a 10-12 minutes video call," stated Thomas Smeenk, CEO. "This partnership brings together Hemostemix's regenerative medicine with insurer-reimbursed, cutting-edge diagnostics. It provides the physicians assessing patients for vascular dementia, including assessments for the Phase I trial, with a highly accurate early detection of cognitive impairment. With additional assessment, physicians will understand if the impairment is Vascular Dementia and treatable with ACP-01." Croom Lawrence, Co-Founder of added, "Our goal is to change lives through upfront precision cognitive testing, followed by targeted treatment. This combination holds the promise to significantly reduce the massive cost of long-term memory care, as we scale." Learn More or Enroll Today at Hemostemix's original trademark for ACP-01 was VesCell(TM). In a word, VesCell(TM) describes angiogensis as the formation of new neo-circulation. Families seeking answers to various forms of cardiovascular disease including vascular dementia can visit to learn more. Families seeking the MCI Screen test may book a consultation with Croom Lawrence at For more information:Thomas Smeenk - tsmeenk@ | 905-580-4170Croom Lawrence - clawrence@ | 540-878-6754 ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, ACP-01. Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder EM: tsmeenk@ PH: 905-580-4170Croom Lawrence - croom@ | 540-878-6754 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of MCI Screen, and its lead product ACP-01, and the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
17-06-2025
- Business
- Yahoo
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Per Policy 4.1. the Subscriber is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's ongoing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder EM: tsmeenk@ PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
